MYRIANTHOPOULOS VASILEIOS

Assistant Professor, Division of Pharamceutical Chemsitry

 

 

Education

  • Degree in Pharmacy, National and Kapodistrian University of Athens (2002).
  • PhD in medicinal chemistry, Department of Pharmacy, National and Kapodistrian University of Athens (2010).
  • Postdoctoral training (2010-2018):
    • Structural Genomics Consortium, University of Oxford, UK.
    • Target Discovery Institute, University of Oxford, UK.
    • Department of Pharmacy, National and Kapodistrian University of Athens.
    • “Athena” Research Centre.

Research topics

  • Rational drug design.
  • Molecular simulations and computational chemistry.
  • Biophysical methods in drug discovery.
  • Chemical biology.
  • Epigenetics, protein kinases, metabolic enzymes, cellular senescence.

Distinctions

  • 4 awards for poster presentations in national and international conferences.
  • STSM Grant, EU-COST TD0905 (2013).
  • Greek Ministry of Education EPEAEK scholarship for postgraduate studies (2002).

Recent publications

  • MyrianthopoulosV, VasileiouP,EvangelouK, CooksK, VassilakopoulosT, PangalisG, KittasG, GeorgakilasA, Gorgoulis V. “Senescence and senotherapeutics: a new field in cancer therapy.” Pharmacology and Therapeutics, 2019, 193, 31-49.
  • Giannakopoulou E, Pardali V, Frakolaki E, Siozos V, Myrianthopoulos V, Mikros E, Taylor M, Kelly J, Vassilaki N, Zoidis G. “Scaffold Hybridization Strategy towards potent hydroxamate-based inhibitors of Flaviviridae viruses and Trypanosoma species.” MedChemComm, 2019, 10, 991-1006.
  • Myrianthopoulos V, Lozach O, Zareifi D, Alexopoulos L, Meijer L, Gorgoulis G. V, Mikros E. “Combined virtual and experimental screening for CK1 inhibitors identifies a modulator of p53 and reveals important aspects of in silico screening performance.” International Journal of Molecular Sciences, 2017, 18, 2102.
  • Myrianthopoulos V, Gaboriaud-Kolar N, Tallant C, Hall ML, Grigoriou S, Brownlee PM, Fedorov O, Rogers C, Heidenreich D, Wanior M, Drosos N, Mexia N, Savitsky P, Bagratuni T, Kastritis E, Terpos E, Filippakopoulos P, Müller S, Skaltsounis AL, Downs JA, Knapp S, Mikros E. “Discovery and optimization of a selective ligand for the Switch/Sucrose Non-Fermenting-related bromodomains of Polybromo protein-1 by the use of virtual screening and hydration analysis.” Journal of Medicinal Chemistry, 2016, 59, 8787-8803.
  • Druzhyna N, Szczesny B, Olah G, Módis K, Asimakopoulou A, Pavlidou A, Szoleczky P, Gerö D, Yanagi K, Törö G, López-García I, Myrianthopoulos V, Mikros E, Zatarain JR, Chao C, Papapetropoulos A, Hellmich MR, Szabo C. “Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer.” Pharmacological Research, 2016, 113 (Pt A), 18-37.
  • Myrianthopoulos V, Cartron P. F, Liutkevičiūtė Z, Klimasauskas S, Matulis D, Bronner C, Martinet N, Mikros E. “Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating DNA methylation.” European Journal of Medicinal Chemistry,2016, 114, 390-396.
  • Myrianthopoulos V, Kritsanida M, Gaboriaud-Kolar N, Magiatis P, Ferandin Y, Durieu E, Lozach O, Cappel D, Soudararahan M, Filippakopoulos P, Sherman W, Knapp S, Meijer L, Mikros E, Skaltsounis AL. “Novel inverse binding mode of indirubin derivatives yields improved selectivity for DYRK kinases.” ACS Medicinal Chemistry Letters, 2013, 4, 22-26.

Contact

Postal address: Section of Pharmaceutical Chemistry,
Department of Pharmacy,
National and Kapodistrian University of Athens,
Panepistimiopolis Zografou, 157 84
Athens, Greece
Tel.: +30(210) 727 4824
Fax: +30(210) 727 4747
e-mail: vmyriant@pharm.uoa.gr